Three Genmab cancer drugs close in on big milestones in 2023
An approval of drug candidate epcoritomab is Genmab’s biggest New Year’s resolution – but three other cancer candidates also have development goals in 2023.
by marketwire, translated by daniel pedersen
Genmab is expecting to reach several significant milestones in 2023 – a year that will also make it clear which types of cancer the company will target with its two candidates, GEN1042 and GEN1046.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab gets new MS market rival after fresh FDA approval
For subscribers
